Chinese language medtech Baird Clinical to head public thru SPAC merger (XFIN)

Futuristic diagnosis and treatment concept

ClaudioVentrella/iStock by the use of Getty Pictures

Chinese language medtech Baird Clinical (BDMD) plans to head public thru a merger with SPAC ExcelFin Acquisition Corp. (NASDAQ:XFIN).

The deal pegs the undertaking worth of the blended corporate at $370M, with stocks anticipated to business on Nasdaq underneath the emblem BDMD.


Risk Warning: 74-89% of retail investor accounts lose money when trading CFDs . You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money